Digital health case studyPharmaceutical

Identifying Ventures With Proven Digital Biomarker Scoring Capability

Client context: Global pharmaceutical

Strategic question

Which ventures have a proven, differentiated digital biomarker scoring algorithm in oncology?

Decision enabled

What the client could do next

Enabled the team to focus evaluation effort on the small number of ventures with defensible proof.

Approach

Powered by HealthTech Alpha, we evaluated 110 ventures across eight priority markets, applied client criteria to build a prioritised list of 15, and mapped their strategic partnerships to pinpoint the most engagement-ready.

Methodology

DefineClarified the strategic question, scope, decision owner and evaluation criteria.

MapIdentified relevant ventures, markets, competitors, partnerships and ecosystem signals.

AssessEvaluated maturity, traction, evidence, strategic fit and operational readiness.

DecideTranslated findings into a decision-ready shortlist, benchmark or recommendation.

Strategic interpretation

Replaced noisy marketing claims with a comparative, evidence-based view of who genuinely has the capability.

Key results

5Priority markets

110Ventures evaluated against criteria

15Prioritised shortlist

Structured digital health intelligence, venture evidence, and analyst interpretation for defensible decisions.

Alpha Brief

Turn this case study into your own decision brief

Answer a few prompts and request a scoped Alpha Brief for your market, portfolio, competitive intelligence, or due diligence question.

Build an Alpha Brief

Request a scoped proposal from this case

Identifying Ventures With Proven Digital Biomarker Scoring Capability

Which ventures have a proven, differentiated digital biomarker scoring algorithm in oncology?

What the client could do next

Approach

Methodology

Strategic interpretation

Overview

Category

Stage

Total Funding

GGA Score